SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001477932-22-000159
Filing Date
2022-01-07
Accepted
2022-01-07 16:30:53
Documents
15
Period of Report
2022-01-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K curr_8k.htm   iXBRL 8-K 21808
2 FORBEARANCE AGREEMENT curr_ex101.htm EX-10.1 27947
  Complete submission text file 0001477932-22-000159.txt   168217

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA curr-20220105.xsd EX-101.SCH 5637
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE curr-20220105_lab.xml EX-101.LAB 12730
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE curr-20220105_cal.xml EX-101.CAL 918
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE curr-20220105_pre.xml EX-101.PRE 8021
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE curr-20220105_def.xml EX-101.DEF 2125
9 EXTRACTED XBRL INSTANCE DOCUMENT curr_8k_htm.xml XML 3178
Mailing Address 1620 BEACON PLACE OXNARD CA 93033
Business Address 1620 BEACON PLACE OXNARD CA 93033 805-824-0410
Cure Pharmaceutical Holding Corp. (Filer) CIK: 0001643301 (see all company filings)

IRS No.: 371765151 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55908 | Film No.: 22518520
SIC: 2834 Pharmaceutical Preparations